

*HTA Network, February 9<sup>th</sup> 2018*

# **PRINCIPLES of PATIENTS and CONSUMERS ENGAGEMENT in HTA**

*(Proposed by the HTA Network Stakeholder Pool - patients and consumers -  
prior to the Legislative Proposal on the future EU Cooperation in HTA)*

The background features abstract, overlapping geometric shapes in various shades of blue, ranging from light sky blue to deep navy blue. These shapes are primarily located on the right side of the slide, creating a modern, dynamic feel.

▶ *Why should Patients and Consumers  
be involved in HTA?*



INCLUSION



LEGITIMACY



TRANSPARENCY-  
VISIBILITY



PUBLICITY



RELEVANCE



APPEAL



RESPONSIBILITY



ENFORCEABILITY

## INCLUSION

- Patients and Consumers shall be Included in procedures that affect their lives

## LEGITIMACY

- Once accepted, Patients and Consumers should be involved with equal credibility as other experts and participants

## TRANSPARENCY/VISIBILITY

- Possibility to recognize that someone who represents Patients and Consumers has taken parts in the HTA procedure (and how)

## PUBLICITY

- HTA procedures (and conclusions) should be clearly understandable, accessible and verifiable for the widest possible audience

## RELEVANCE

- The information on which the assessment is based must be able to justify the conclusion

## APPEAL/REVISABILITY

- Provide for a mechanism to ensure the possibility of an appeal on the procedure.  
( Divergence on conditions: in case of new evidence and/or in case of concerns raised by stakeholders )

## RESPONSIBILITY

- Playing by the rules: when Patients and Consumers are consulted in an appropriate manner and they agree with the methods, they accept the conclusion

## ENFORCEABILITY

- The procedure should assure that the prior conditions are met

*HTA Network, February 9<sup>th</sup> 2018*

# CRITERIA FOR PRIORITISATION OF TECHNOLOGIES FOR JOINT HTA

*(Proposed by the HTA Network Stakeholder Pool - patients and consumers -  
prior to the Legislative Proposal on the future EU Cooperation in HTA)*

# (I) Pharmaceuticals

## ▶ PRIORITISATION CRITERIA

(Proposal of at least 3 out of 5 criteria to be met?)

ADVANCED  
THERAPIES

ORPHANS for  
which not all  
MS have  
expertise

OTHERS

- ▶ Complex / Disruptive technologies
- ▶ Benefit/risk not clear
- ▶ Significant increased use (e.g. off label)
- ▶ (Antimicrobiological products targeting resistant strains)
- ▶ (High estimated budget impact)

## **(II) Non - Pharmaceuticals**


- ▶ **Invasive and/or implanted medical devices**
- ▶ **Connected devices or apps implying privacy risks or substituting HCP for diagnosis**
- ▶ **Complex surgery**
- ▶ **Disruptive technologies with impact on organisation of healthcare**
- ▶ **Prevention programmes requiring cross-border actions**

## (III) Obsolete technologies

Pharmaceuticals

**OBSOLETE  
TECHNOLOGIES**

Non -  
Pharmaceuticals





**Questions ?**